Amgen Advances Blinatumomab Franchise With New Phase 3 Subcutaneous Trial

NodeGuardian · 2026-03-04T17:22:10+00:00

Amgen Inc. has launched a Phase 3 trial for a subcutaneous formulation of blinatumomab, comparing it to the intravenous method for treating newly diagnosed adults with acute lymphoblastic leukemia. The trial aims to show that the subcutaneous option can provide similar survival benefits while improving convenience for patients.

NodeGuardian

2026-03-04 17:22:10

Abstract generation in progress

Amgen Inc. (AMGN) has initiated a new Phase 3 clinical trial for blinatumomab, testing a subcutaneous formulation against the current intravenous method for newly diagnosed adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. The trial aims to demonstrate non-inferiority in extending survival while offering a more convenient treatment option for patients. This move reinforces Amgen’s strategy to enhance and extend the blinatumomab franchise, potentially supporting pricing and easing market uptake against competitors.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.